Related Experiment Video

Updated: Jul 4, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
07:21

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal

Wenhua Piao1, Yu Wang, Yasushi Adachi

  • 1First Department of Internal Medicine, Sapporo Medical University, Chuo-ku, Sapporo 060-8543, Japan.

Molecular Cancer Therapeutics
|June 21, 2008
PubMed

Insights

A new drug, NVP-AEW541, effectively inhibits insulin-like growth factor-I receptor (IGF-IR) signaling, suppressing gastrointestinal cancer growth and enhancing chemotherapy effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Insulin-like growth factor-I receptor (IGF-IR) signaling drives gastrointestinal (GI) cancer growth and proliferation.
  • Targeting IGF-IR is a potential therapeutic strategy for GI carcinomas.

Purpose of the Study:

  • To evaluate the efficacy of NVP-AEW541, a novel IGF-IR tyrosine kinase inhibitor, in GI cancer.
  • To assess its impact on signal transduction, proliferation, survival, and migration in various GI cancer cell lines.
  • To investigate its effects alone and in combination with chemotherapy in vitro and in vivo.

Main Methods:

  • NVP-AEW541 treatment of colorectal, pancreatic, esophageal, and liver cancer cell lines.
  • In vitro and nude mouse xenograft studies evaluating tumor growth, apoptosis, and cell migration.
  • Analysis of IGF-IR and insulin signaling pathways, including hybrid receptor formation.

Main Results:

  • NVP-AEW541 effectively blocked IGF-IR autophosphorylation and downstream signaling (Akt, ERK) activated by IGF.
  • The drug suppressed proliferation, tumorigenicity, and migration in all tested GI cancer cell lines.
  • NVP-AEW541 enhanced chemotherapy-induced apoptosis and tumor inhibition in vitro and in vivo.

Conclusions:

  • NVP-AEW541 demonstrates significant therapeutic potential for human GI carcinomas.
  • It may be effective as a single agent or in combination with chemotherapy.
  • The compound selectively targets IGF-IR signaling without affecting insulin signaling or hybrid receptor formation.

More Related Videos

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib06:43

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...